Search Results 2851-2860 of 18402 for rheumatoid arthritis

  1. A Study To Assess Efficacy And Safety Of Pembrolizumab With Or Without Sacituzumab Tirumotecan (MK- 2870) In Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - Mayo Clinic

    * Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as ...

  2. Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies - Mayo Clinic

    ... factor [VEGF] Trap) are allowed; Surgery within two weeks prior to registration; Significant hemorrhage (> 30mL bleeding/episode in previous 3 months) or ...

  3. A Study of Ibrutinib as Prophylaxis for Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT) - Mayo Clinic

    ... factor support;; Platelet count ≥ 50,000/mm^3 (*Untransfused);; PT/INR/aPTT ≤ 1.5 x ULN;; Total bilirubin ≤ 1.5 x ULN (unless it is due to Gilbert's ...

  4. ACL Archives - Mayo Clinic News Network

    prevention and treatment, Mayo Clinic is joining an Arthritis Foundation-funded study to analyze damaged cartilage before osteoarthritis sets in. Researchers ...

  5. Targeted Drug Therapy Clinical Trials - Mayo Clinic Research

    ... factor receptor 2 (FGFR2). Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Neratinib +/- ...

  6. A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma - Mayo Clinic

    ... factor support, or medically significant need for intervention. For subjects with presumptive evidence of transformation based on clinical assessment of ...

  7. Thomas Rieck Archives - Mayo Clinic News Network

    Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It occurs when the protective cartilage on the ends of your bones ...

  8. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta - Mayo Clinic

    hypophosphatasia). - History of Kawasaki disease, rheumatic myocarditis, ischemic cardiomyopathy, inherited cardiomyopathies, nephrotic syndrome, familial ...

  9. Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy - Mayo Clinic

    ... factor receptor 2 (HER2). Patients must not have received any prior chemotherapy, or endocrine therapy for their current breast cancer. Patients who ...

  10. Medical Research & Education - Mayo Clinic News Network

    Race and Insurance Status Factor into Cancer Surgery for Women. Mayo Clinic Staff. January 8, 2016. Research. Genomic Rearrangement Drives Pancreatic Cancer.